ERBB2 and breast cancer: Apart from weight gain and obesity which is associated with detrimental effect on health profiles, anti-cancer drugs, specifically the anthracyclines and anti-human epidermal growth factor receptor 2 (HER2) agents that are commonly used in breast cancer, could cause cardiotoxicity and may further increase the cardiovascular risk of the patients concerned [16].